NCT01002183 (JP015) is a Phase 2 clinical trial of Fosmidomycin in Malaria, sponsored by Jomaa Pharma GmbH.

Who is sponsoring NCT01002183?

NCT01002183 is sponsored by Jomaa Pharma GmbH.

What drugs are being tested in NCT01002183?

Interventions in NCT01002183: Fosmidomycin.

Is NCT01002183 still recruiting?

NCT01002183 is currently withdrawn. Last updated 26 September 2011.

Last reviewed 2011-09-26 · How we verify

NCT01002183: JP015

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria

Withdrawn Phase 2 Last updated 26 September 2011

What this trial tests

Phase 2 trial testing Fosmidomycin in Malaria in 40 participants. Withdrawn.

Quick facts

Lead sponsor	Jomaa Pharma GmbH
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Sites	1 location across Thailand

Drugs / interventions tested

Fosmidomycin — full drug profile →

Conditions studied

Malaria — all drugs for Malaria →

Sponsor

Jomaa Pharma GmbH — full company profile →

Who can join

Adults 15 to 55, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy of fosmidomycin and clindamycin/artesunate when co-administered to adults with acute uncomplicated P.f. malaria.
Time frame: 12 months

Sponsor's own description

The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.
Guggisberg AM, Sundararaman SA, Lanaspa M, Moraleda C, et al · · 2016 · cited 26× · PMID 27443612 · DOI 10.1093/infdis/jiw304

Verify or expand the search:

Other recruiting trials for Malaria

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01002183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jomaa Pharma GmbH
Last refreshed: 26 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01002183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing